CAS: 147804-30-6; Tert-Butyl 1-Oxa-6-Azaspiro[2.5]Octane-6-Carboxylate

该化合物是一种循环化合物,在硬性双环框架内具有氧和亚萨功能,其保护基-丁基碳氢化合物(Boc)组增强了稳定性,使之适合用于医药化学和有机合成的合成应用.该环球结构提供了可影响环开反应或功能化反应的回动性和选择性的僵化限制.这一化合物作为复合体的构件,作为准备复杂的异性循环或生物活性分子的前体,具有特别宝贵的价值.其定义明确的立体化学学和与标准反应条件的兼容性,使它成为药物研发的多功能中间体.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

N-叔丁氧羰基-4-哌啶酮 N-Tert-Butyloxycarbonylpiperidin-4-One 79099-07-3
N-Boc-4-亚甲基哌啶 Tert-Butyl 4-Methylidenepiperidine-1-Carboxylate 159635-49-1

合成工艺路线路线简述

    4-乙烯基-哌啶置于间氯过氧苯甲酸体系中,用 氯仿 用作溶剂,化学反应 0.5H,以90.2%的收率获得1-噁-6-氮杂螺[2.5]辛烷-6-羧酸-1,1-二甲基乙酯
    参考文献: Antibacterial Aminoglycoside Analogs[fr] Analogues D'Aminoglycosides Antibactériens
    标题: Antibacterial Aminoglycoside Analogs[fr] Analogues D'Aminoglycosides Antibactériens
    摘要:结构(i)的化合物具有抗菌活性,包括立体异构体,药用可接受的盐和前药,其中q1,Q2,Q3,R8和r9如本文所定义.还公开了与制备和使用这些化合物相关的方法,以及包含这些化合物的药物组合物.

    海关参考信息

    专利信息


    专利号:US-6593347-B2
    优先权日:1998-10-30
    标题 :Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
    发明人:BANDARAGE UPUL K; DONG QING; FANG XINQIN; GARVEY DAVID S; MERCER GREGORY J; RICHARDSON STEWART K; SCHROEDER JOSEPH D; WANG TIANSHENG
    权利人:NITROMED INC
    摘要:The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

    专利号:WO-2009011653-A1
    优先权日:2007-07-17
    标题:A process for the preparation of intermediates and their us in the synthesis of spiropiperidine compounds

    专利号:US-9168248-B2
    优先权日:2009-02-17
    标 题:Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
    发明人:LACHANCE NICOLAS; LECLERC JEAN-PHILIPPE; LI CHUN SING; MORADEI OSCAR MIGUEL
    权利人:LACHANCE NICOLAS; LECLERC JEAN-PHILIPPE; LI CHUN SING; MORADEI OSCAR MIGUEL; MERCK CANADA INC
    摘要:Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

    专利号:US-8785632-B2
    优先权日:2004-08-26
    标 题:Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
    发明人:CUI JINGRONG JEAN; FUNK LEE ANDREW; JIA LEI; KUNG PEI-PEI; MENG JERRY JIALUN; NAMBU MITCHELL DAVID; PAIRISH MASON ALAN; SHEN HONG; TRAN-DUBE MICHELLE
    权利人:CUI JINGRONG JEAN; FUNK LEE ANDREW; JIA LEI; KUNG PEI-PEI; MENG JERRY JIALUN; NAMBU MITCHELL DAVID; PAIRISH MASON ALAN; SHEN HONG; TRAN-DUBE MICHELLE; AGOURON PHARMA; PFIZER
    摘要:Enantiomerically pure compound of formula 1 n nare provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

    专利号:AU-2007275931-A1
    优先权日:2006-07-19
    标 题:Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity

    专利号:AU-2007275931-B2
    优先权日:2006-07-19
    标题:Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
    威智医药股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.viwit.com
    企业联系电话:0632-2980981;15063270987👤
    📞威智医药股份有限公司 ⚠️参考联系方式
    联系人:翁经理
    电话:0632-2980981;15063270987
    手机:15063270987
    传真:QQ2730058784
    邮箱:service.china3@viwit.com
    通信地址: 山东省滕州市生物医药产业基地威智大道88号
    邮编: 277514
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:山东省滕州市生物医药产业基地威智大道88号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知